MannKind Stock Price, News & Analysis (NASDAQ:MNKD)

$2.99 +0.06 (+2.05 %)
(As of 02/19/2018 11:00 AM ET)
Previous Close$2.93
Today's Range$2.87 - $3.22
52-Week Range$0.67 - $6.96
Volume3.34 million shs
Average Volume5.01 million shs
Market Capitalization$355.42 million
P/E Ratio-11.07
Dividend YieldN/A
Beta3.18

About MannKind (NASDAQ:MNKD)

MannKind logoMannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Receive MNKD News and Ratings via Email

Sign-up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MNKD
CUSIP56400P20
Phone818-661-5000

Debt

Debt-to-Equity Ratio-0.43%
Current Ratio0.31%
Quick Ratio0.28%

Price-To-Earnings

Trailing P/E Ratio-11.0740740740741
Forward P/E Ratio-2.65
P/E GrowthN/A

Sales & Book Value

Annual Sales$174.76 million
Price / Sales2.03
Cash Flow$0.60 per share
Price / Cash4.95
Book Value($1.92) per share
Price / Book-1.56

Profitability

Trailing EPS($0.27)
Net Income$125.66 million
Net Margins-155.83%
Return on Equity-24.93%
Return on Assets-130.34%

Miscellaneous

Employees153
Outstanding Shares118,870,000

MannKind (NASDAQ:MNKD) Frequently Asked Questions

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) announced its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.11. The biopharmaceutical company had revenue of $2.04 million for the quarter, compared to analyst estimates of $2.56 million. MannKind had a negative return on equity of 24.93% and a negative net margin of 155.83%. The business's revenue for the quarter was down 98.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.30 EPS. View MannKind's Earnings History.

When will MannKind make its next earnings announcement?

MannKind is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for MannKind.

Where is MannKind's stock going? Where will MannKind's stock price be in 2018?

4 analysts have issued 12 month price targets for MannKind's shares. Their predictions range from $1.00 to $2.77. On average, they expect MannKind's share price to reach $1.89 in the next year. View Analyst Ratings for MannKind.

What are Wall Street analysts saying about MannKind stock?

Here are some recent quotes from research analysts about MannKind stock:

  • 1. According to Zacks Investment Research, "Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung. " (1/10/2018)
  • 2. Maxim Group analysts commented, "MannKind raised (net $57.7M) in an equity offering recently. We had anticipated a larger offering that would provide a longer capital runway to get the Afrezza launch off the ground; one that would provide adequate support to launch a new product in a mature market." (11/1/2017)

Are investors shorting MannKind?

MannKind saw a increase in short interest in January. As of January 31st, there was short interest totalling 34,425,319 shares, an increase of 4.4% from the January 12th total of 32,969,296 shares. Based on an average daily trading volume, of 8,223,627 shares, the days-to-cover ratio is presently 4.2 days. Approximately 34.5% of the company's shares are short sold.

Who are some of MannKind's key competitors?

Who are MannKind's key executives?

MannKind's management team includes the folowing people:

  • Kent Kresa, Chairman of the Board (Age 78)
  • Michael E. Castagna Pharm.D., Chief Executive Officer, Director (Age 40)
  • Rosabel R. Alinaya, Acting Chief Financial Officer, Senior Vice President, Chief Accounting Officer (Age 56)
  • Steven B Binder, Chief Financial Officer, Principal Accounting Officer (Age 54)
  • Linda Adreveno, Senior Vice President - Human Resources (Age 60)
  • Joseph Kocinsky, Chief Technology Officer, Corporate Vice President (Age 52)
  • David B. Thomson Ph.D., J.D., Corporate Vice President, General Counsel, Corporate Secretary (Age 49)
  • Patrick McCauley J.D., Chief Commercial Officer
  • Stuart A. Tross Ph.D., Chief People Officer (Age 49)
  • James Samuel Shannon M.D., Director (Age 60)

Who owns MannKind stock?

MannKind's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.97%), Geode Capital Management LLC (0.46%), Dupont Capital Management Corp (0.17%), Schwab Charles Investment Management Inc. (0.16%), Two Sigma Advisers LP (0.14%) and Millennium Management LLC (0.14%). Company insiders that own MannKind stock include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Raymond W Urbanski, Rosabel Realica Alinaya and Stuart A Tross. View Institutional Ownership Trends for MannKind.

Who sold MannKind stock? Who is selling MannKind stock?

MannKind's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for MannKind.

Who bought MannKind stock? Who is buying MannKind stock?

MannKind's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Two Sigma Advisers LP, Zeke Capital Advisors LLC, Dupont Capital Management Corp, Schwab Charles Investment Management Inc., Geode Capital Management LLC, Wells Fargo & Company MN and Raymond James & Associates. Company insiders that have bought MannKind stock in the last two years include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Rosabel Realica Alinaya and Stuart A Tross. View Insider Buying and Selling for MannKind.

How do I buy MannKind stock?

Shares of MannKind can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MannKind's stock price today?

One share of MannKind stock can currently be purchased for approximately $2.99.

How big of a company is MannKind?

MannKind has a market capitalization of $355.42 million and generates $174.76 million in revenue each year. The biopharmaceutical company earns $125.66 million in net income (profit) each year or ($0.27) on an earnings per share basis. MannKind employs 153 workers across the globe.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 301, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]


MarketBeat Community Rating for MannKind (MNKD)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  282 (Vote Outperform)
Underperform Votes:  383 (Vote Underperform)
Total Votes:  665
MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MannKind (NASDAQ:MNKD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldSell
Consensus Rating Score: 1.751.751.751.00
Ratings Breakdown: 2 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $1.89$0.92$0.92$0.92
Price Target Upside: 28.33% downside71.85% downside71.85% downside19.03% downside

MannKind (NASDAQ:MNKD) Consensus Price Target History

Price Target History for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ:MNKD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/30/2018Maxim GroupReiterated RatingHoldMediumView Rating Details
1/25/2018S&P Equity ResearchLower Price Target$3.49 -> $2.77HighView Rating Details
11/8/2017HC WainwrightReiterated RatingBuyN/AView Rating Details
5/22/2017JPMorgan Chase & Co.Reiterated RatingUnderweightHighView Rating Details
5/11/2017Piper Jaffray CompaniesSet Price TargetSell$1.00MediumView Rating Details
6/1/2016Royal Bank of CanadaLower Price TargetUnderperform$1.00 -> $0.15N/AView Rating Details
4/28/2016JMP SecuritiesReiterated RatingHoldN/AView Rating Details
4/1/2016Goldman Sachs GroupReiterated RatingSellN/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

MannKind (NASDAQ:MNKD) Earnings History and Estimates Chart

Earnings by Quarter for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ MNKD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018        
11/7/2017Q3 2017($0.20)($0.31)$2.56 million$2.04 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.25)($0.35)$2.75 million$2.16 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.09)($0.17)$3.50 million$3.00 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.20)($0.19)$6.00 million$12.40 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.06)$0.26$2.00 million$162.35 millionViewListenView Earnings Details
8/8/2016Q2($0.06)($0.07)$0.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.06)ViewN/AView Earnings Details
3/14/2016Q4($0.05)($0.66)$0.35 millionViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.08)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.07)$0.53 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.08)$5.40 millionViewListenView Earnings Details
2/24/2015Q414($0.09)($0.09)$3.13 millionViewListenView Earnings Details
11/3/2014Q314$0.09($0.09)$66.60 millionViewListenView Earnings Details
8/11/2014Q214($0.11)($0.19)ViewListenView Earnings Details
5/12/2014Q114($0.13)($0.14)ViewListenView Earnings Details
2/18/2014Q4($0.14)($0.16)$0.43 millionViewListenView Earnings Details
11/4/2013Q313($0.14)($0.17)ViewListenView Earnings Details
8/9/2013Q2 2013($0.14)($0.16)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.15)($0.15)ViewListenView Earnings Details
2/11/2013Q4 2012($0.19)($0.23)ViewListenView Earnings Details
11/1/2012Q312($0.24)($0.22)ViewN/AView Earnings Details
8/7/2012($0.24)($0.23)ViewN/AView Earnings Details
5/9/2012($0.23)($0.27)ViewN/AView Earnings Details
2/22/2012($0.32)($0.30)ViewN/AView Earnings Details
11/3/2011($0.32)($0.31)ViewN/AView Earnings Details
8/4/2011($0.30)($0.37)ViewN/AView Earnings Details
5/9/2011($0.29)($0.34)ViewN/AView Earnings Details
2/10/2011($0.40)($0.33)ViewN/AView Earnings Details
10/29/2010Q3 2010($1.95)($2.00)ViewN/AView Earnings Details
8/2/2010Q2 2010($2.00)($1.87)ViewN/AView Earnings Details
4/30/2010Q1 2010($2.20)($1.98)ViewN/AView Earnings Details
2/1/2010Q4 2009($2.05)($2.64)ViewN/AView Earnings Details
11/2/2009Q3 2009($2.45)($2.10)ViewN/AView Earnings Details
8/3/2009Q2 2009($2.80)($2.72)ViewN/AView Earnings Details
5/4/2009Q1 2009($3.25)($2.91)ViewN/AView Earnings Details
2/17/2009Q4 2008($3.20)($4.10)ViewN/AView Earnings Details
11/5/2008Q3 2008($4.00)($3.37)ViewN/AView Earnings Details
8/11/2008Q2 2008($3.70)($3.94)ViewN/AView Earnings Details
5/5/2008Q1 2008($3.90)($3.52)ViewN/AView Earnings Details
3/4/2008Q4 2007($3.90)($3.77)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

MannKind (NASDAQ:MNKD) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.13 EPS
Next Year EPS Consensus Estimate: $-0.98 EPS

Dividends

Dividend History for MannKind (NASDAQ:MNKD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

MannKind (NASDAQ MNKD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.10%
Institutional Ownership Percentage: 14.86%
Insider Trades by Quarter for MannKind (NASDAQ:MNKD)
Institutional Ownership by Quarter for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ MNKD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/21/2017Stuart A TrossVPBuy39,840$2.52$100,396.8059,840View SEC Filing  
12/20/2017Michael CastagnaCEOBuy8,000$2.29$18,320.0035,532View SEC Filing  
10/13/2017Kent KresaDirectorBuy166,600$6.00$999,600.00View SEC Filing  
8/10/2017Raymond W UrbanskiCMOSell296$1.15$340.402,924View SEC Filing  
6/30/2017Rosabel Realica AlinayaSVPBuy2,000$1.23$2,460.0030,091View SEC Filing  
1/3/2017Matthew J PfefferCEOBuy4,540$0.54$2,451.60403,085View SEC Filing  
1/3/2017Rosabel Realica AlinayaSVPBuy9,043$0.54$4,883.22140,456View SEC Filing  
8/26/2016Michael CastagnaInsiderBuy17,500$0.78$13,650.00212,500View SEC Filing  
8/24/2016Michael CastagnaInsiderBuy15,000$0.87$13,050.00195,000View SEC Filing  
8/23/2016Michael CastagnaInsiderBuy25,000$0.94$23,500.00180,000View SEC Filing  
8/15/2016Matthew J PfefferCEOBuy25,000$0.99$24,750.00397,996View SEC Filing  
8/12/2016Michael CastagnaInsiderBuy25,000$1.00$25,000.0075,000View SEC Filing  
5/17/2016Michael CastagnaInsiderBuy50,000$0.93$46,500.0050,000View SEC Filing  
4/24/2015Hakan EdstromCEOSell73,460$4.83$354,811.80View SEC Filing  
3/27/2015Hakan EdstromCEOSell73,460$5.21$382,726.60View SEC Filing  
2/10/2015Hakan EdstromCEOSell73,460$7.75$569,315.00View SEC Filing  
2/5/2015David ThomsonVPSell80,000$7.00$560,000.00View SEC Filing  
1/5/2015Diane PalumboVPSell188,999$5.95$1,124,544.05View SEC Filing  
11/24/2014David ThomsonVPSell118,114$6.14$725,219.96View SEC Filing  
10/3/2014Juergen MartensVPSell63,800$5.48$349,624.00View SEC Filing  
8/27/2014Juergen MartensVPSell417$7.60$3,169.20View SEC Filing  
8/7/2014David ThomsonVPSell30,000$8.16$244,800.00View SEC Filing  
7/21/2014Juergen MartensVPSell26,458$9.65$255,319.70View SEC Filing  
7/15/2014Diane PalumboVPSell17,901$10.01$179,189.01View SEC Filing  
7/1/2014Matthew J PfefferCFOSell20,000$10.44$208,800.00View SEC Filing  
6/30/2014Hakan EdstromCOOBuy1,692$4.42$7,478.64View SEC Filing  
6/27/2014Juergen MartensVPSell25,417$10.53$267,641.01View SEC Filing  
6/26/2014David ThomsonVPSell30,000$10.51$315,300.00View SEC Filing  
6/20/2014Juergen MartensVPSell1,458$10.34$15,075.72View SEC Filing  
6/16/2014Diane PalumboVPSell17,902$10.59$189,582.18View SEC Filing  
6/5/2014Juergen MartensVPSell120,000$11.00$1,320,000.00View SEC Filing  
6/4/2014David ThomsonVPSell133,000$9.95$1,323,350.00View SEC Filing  
6/3/2014Diane PalumboVPSell52,957$9.50$503,091.50View SEC Filing  
5/23/2014Juergen MartensVPSell25,000$7.65$191,250.00View SEC Filing  
5/19/2014Juergen MartensVPSell76,899$7.50$576,742.50139,024View SEC Filing  
5/15/2014Diane PalumboVPSell18,176$7.06$128,322.56158,858View SEC Filing  
1/24/2014Juergen MartensVPSell50,000$5.56$278,000.00139,450View SEC Filing  
12/31/2013Hakan EdstromCOOBuy1,589$4.53$7,198.17729,685View SEC Filing  
12/20/2013Juergen MartensVPSell32,054$5.00$160,270.00139,450View SEC Filing  
12/11/2013David ThomsonVPSell150,000$5.00$750,000.0083,752View SEC Filing  
11/29/2013Juergen MartensVPSell48,057$5.01$240,765.57171,504View SEC Filing  
11/15/2013Diane PalumboVPSell25,000$5.02$125,500.00112,756View SEC Filing  
8/28/2013David ThomsonVPSell19,204$5.78$110,999.1240,082View SEC Filing  
8/26/2013Juergen MartensVPSell20,000$5.52$110,400.00136,016View SEC Filing  
8/1/2013Matthew J PfefferCFOSell10,000$8.00$80,000.00View SEC Filing  
7/2/2013Matthew J PfefferCFOSell10,000$7.00$70,000.00View SEC Filing  
6/30/2013Diane PalumboVPBuy1,610$1.96$3,155.60View SEC Filing  
6/30/2013Matthew J PfefferCFOBuy7,448$1.96$14,598.08View SEC Filing  
6/3/2013Diane PalumboVPSell66,849$7.50$501,367.50View SEC Filing  
5/16/2013Diane PalumboVPSell26,829$5.25$140,852.25View SEC Filing  
5/15/2013Matthew J PfefferCFOSell10,000$5.00$50,000.00View SEC Filing  
12/31/2012Matthew J PfefferCFOBuy1,056$1.95$2,059.20View SEC Filing  
12/21/2012Alfred E MannMajor ShareholderBuy40,000,000$2.59$103,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MannKind (NASDAQ MNKD) News Headlines

Source:
DateHeadline
Don’t Buy MannKind Corporation Stock Under Any CircumstancesDon’t Buy MannKind Corporation Stock Under Any Circumstances
investorplace.com - February 12 at 10:14 AM
MannKind Co. (MNKD) Given Consensus Recommendation of "Hold" by AnalystsMannKind Co. (MNKD) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 12 at 1:32 AM
MannKind (MNKD) Lifted to "Hold" at BidaskClubMannKind (MNKD) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - February 10 at 11:52 AM
MannKind - Afrezza Scripts Remain Flat As Company Hires New ExecutiveMannKind - Afrezza Scripts Remain Flat As Company Hires New Executive
seekingalpha.com - February 10 at 9:19 AM
MannKind Co. (MNKD) Short Interest Up 4.4% in JanuaryMannKind Co. (MNKD) Short Interest Up 4.4% in January
www.americanbankingnews.com - February 9 at 4:58 PM
MannKind Corporation Appoints Dr. David Kendall as Chief Medical OfficerMannKind Corporation Appoints Dr. David Kendall as Chief Medical Officer
finance.yahoo.com - February 6 at 9:22 AM
MannKind - Afrezza Scripts Remain Modest - MannKind Corporation ... - Seeking AlphaMannKind - Afrezza Scripts Remain Modest - MannKind Corporation ... - Seeking Alpha
seekingalpha.com - February 4 at 4:28 PM
MannKind (MNKD) Rating Lowered to Sell at BidaskClubMannKind (MNKD) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - February 3 at 7:40 PM
MannKind (MNKD) Receives "Hold" Rating from Maxim GroupMannKind (MNKD) Receives "Hold" Rating from Maxim Group
www.americanbankingnews.com - January 30 at 4:18 PM
Here's Why MannKind Briefly Spiked TodayHere's Why MannKind Briefly Spiked Today
finance.yahoo.com - January 30 at 9:56 AM
MannKind (MNKD) Raised to Hold at BidaskClubMannKind (MNKD) Raised to Hold at BidaskClub
www.americanbankingnews.com - January 27 at 2:52 PM
Why MannKind Corporation Stock Is Falling Back to Earth TodayWhy MannKind Corporation Stock Is Falling Back to Earth Today
www.fool.com - January 26 at 1:14 PM
Is MannKind Corporation Stock Really Worth the Risk?Is MannKind Corporation Stock Really Worth the Risk?
investorplace.com - January 26 at 10:24 AM
S&P Equity Research Lowers MannKind (MNKD) Price Target to $2.77S&P Equity Research Lowers MannKind (MNKD) Price Target to $2.77
www.americanbankingnews.com - January 25 at 4:10 PM
The Most Likely Reason Why MannKind Corporation Skyrocketed Higher TodayThe Most Likely Reason Why MannKind Corporation Skyrocketed Higher Today
www.fool.com - January 25 at 3:10 PM
MannKind latest biotech breakout, up 32%MannKind latest biotech breakout, up 32%
seekingalpha.com - January 25 at 12:39 PM
The Simple Reason Why I Won't Buy MannKind Corporation StockThe Simple Reason Why I Won't Buy MannKind Corporation Stock
finance.yahoo.com - January 18 at 10:40 AM
The Simple Reason Why I Wont Buy MannKind Corporation StockThe Simple Reason Why I Won't Buy MannKind Corporation Stock
www.fool.com - January 18 at 10:28 AM
MannKind Co. (MNKD) Receives Consensus Rating of "Hold" from BrokeragesMannKind Co. (MNKD) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 18 at 1:08 AM
MannKind Corporation to Present at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor ConferenceMannKind Corporation to Present at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor Conference
finance.yahoo.com - January 16 at 9:48 AM
Financial Survey: CytomX Therapeutics (CTMX) and MannKind (MNKD)Financial Survey: CytomX Therapeutics (CTMX) and MannKind (MNKD)
www.americanbankingnews.com - January 15 at 1:10 AM
MannKind Co. (MNKD) Sees Large Increase in Short InterestMannKind Co. (MNKD) Sees Large Increase in Short Interest
www.americanbankingnews.com - January 12 at 3:14 AM
These Two Updates Caused MannKinds Stock to Plunge 25.9% in December - Motley FoolThese Two Updates Caused MannKind's Stock to Plunge 25.9% in December - Motley Fool
www.fool.com - January 5 at 9:53 AM
These Two Updates Caused MannKind's Stock to Plunge 25.9% in DecemberThese Two Updates Caused MannKind's Stock to Plunge 25.9% in December
finance.yahoo.com - January 5 at 9:53 AM
These Two Updates Caused MannKinds Stock to Plunge 25.9% in December These Two Updates Caused MannKind's Stock to Plunge 25.9% in December
www.fool.com - January 5 at 9:51 AM
Why MannKind Corporation Jumped Higher TodayWhy MannKind Corporation Jumped Higher Today
finance.yahoo.com - January 2 at 6:11 PM
MannKind (MNKD) Raised to "Sell" at ValuEngineMannKind (MNKD) Raised to "Sell" at ValuEngine
www.americanbankingnews.com - December 30 at 11:16 PM
MannKind: Still Looking Weak - Seeking AlphaMannKind: Still Looking Weak - Seeking Alpha
seekingalpha.com - December 29 at 10:18 AM
MannKind CEO, Exec Bought Stock in December - BarronsMannKind CEO, Exec Bought Stock in December - Barron's
www.barrons.com - December 28 at 6:22 AM
Do Options Traders Know Something About MannKind Corp (MNKD) Stock We Don't?Do Options Traders Know Something About MannKind Corp (MNKD) Stock We Don't?
finance.yahoo.com - December 28 at 6:22 AM
[$$] MannKind CEO, Exec Bought Stock in December[$$] MannKind CEO, Exec Bought Stock in December
finance.yahoo.com - December 28 at 6:22 AM
ETFs with exposure to MannKind Corp. : December 25, 2017ETFs with exposure to MannKind Corp. : December 25, 2017
finance.yahoo.com - December 25 at 6:51 PM
MannKind - Scripts, Deerfield, And Insider Buys - Seeking AlphaMannKind - Scripts, Deerfield, And Insider Buys - Seeking Alpha
seekingalpha.com - December 24 at 3:49 AM
MannKind Co. (MNKD) Given Average Recommendation of "Sell" by BrokeragesMannKind Co. (MNKD) Given Average Recommendation of "Sell" by Brokerages
www.americanbankingnews.com - December 24 at 1:31 AM
MannKind (MNKD) Downgraded by BidaskClub to "Sell"MannKind (MNKD) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - December 22 at 7:32 PM
Stuart A. Tross Purchases 39,840 Shares of MannKind Co. (MNKD) StockStuart A. Tross Purchases 39,840 Shares of MannKind Co. (MNKD) Stock
www.americanbankingnews.com - December 21 at 11:36 PM
Insider Buying: MannKind Co. (MNKD) CEO Buys 8,000 Shares of StockInsider Buying: MannKind Co. (MNKD) CEO Buys 8,000 Shares of Stock
www.americanbankingnews.com - December 20 at 6:28 PM
Why Red Hat, MannKind, and Navistar International Slumped TodayWhy Red Hat, MannKind, and Navistar International Slumped Today
finance.yahoo.com - December 20 at 5:04 PM
MannKind (MNKD) Lowered to Sell at Zacks Investment ResearchMannKind (MNKD) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - December 17 at 1:38 PM
ETFs with exposure to MannKind Corp. : December 14, 2017ETFs with exposure to MannKind Corp. : December 14, 2017
finance.yahoo.com - December 14 at 5:37 PM
Why MannKind Corporation Dipped 4.8% in November - Motley FoolWhy MannKind Corporation Dipped 4.8% in November - Motley Fool
www.fool.com - December 7 at 5:30 PM
Why MannKind Corporation Dipped 4.8% in NovemberWhy MannKind Corporation Dipped 4.8% in November
finance.yahoo.com - December 5 at 5:02 PM
MannKind (MNKD) Rating Lowered to Hold at BidaskClubMannKind (MNKD) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - December 2 at 12:40 PM
MannKind Corporation (MNKD) Given Average Rating of "Hold" by BrokeragesMannKind Corporation (MNKD) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 29 at 1:38 AM
Implied Volatility Surging for MannKind (MNKD) Stock OptionsImplied Volatility Surging for MannKind (MNKD) Stock Options
finance.yahoo.com - November 27 at 4:55 PM
ETFs with exposure to MannKind Corp. : November 27, 2017ETFs with exposure to MannKind Corp. : November 27, 2017
finance.yahoo.com - November 27 at 4:55 PM
MannKind Corporation (MNKD) Downgraded by ValuEngine to "Strong Sell"MannKind Corporation (MNKD) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - November 26 at 12:56 PM
MannKind: Afrezza Scripts And Revenue Rising - Is It Enough? - Seeking AlphaMannKind: Afrezza Scripts And Revenue Rising - Is It Enough? - Seeking Alpha
seekingalpha.com - November 25 at 9:33 AM
An Integrated BioSci Research On MannKind Corporation: How To Unlock Value? - Seeking AlphaAn Integrated BioSci Research On MannKind Corporation: How To Unlock Value? - Seeking Alpha
seekingalpha.com - November 23 at 6:32 AM
MannKind Corp. :MNKD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017MannKind Corp. :MNKD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017
finance.yahoo.com - November 22 at 5:24 AM

SEC Filings

MannKind (NASDAQ:MNKD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MannKind (NASDAQ:MNKD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MannKind (NASDAQ MNKD) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.